The effectiveness of enoxaparin in preventing deep vein thrombosis

Phase 3

Recruiting

Conditions: Deep vein thrombosis.
Phlebitis and thrombophlebitis of other deep vessels of lower extremities
I80.2

Registration Number: IRCT20210602051484N1

Lead Sponsor: Zanjan University of Medical Sciences

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Recruiting

Sex: All

Target Recruitment: 200

Inclusion Criteria

Willingness to participate in the study
All patients under 70 years of age do not have coagulation disorders
Not having underlying diseases associated with DVT
All patients have symptomatic gallstones (abdominal pain, nausea and vomiting after eating)
Simultaneous existence of gallbladder polyps and gallstones
Diabetic people with gallstones
Patients with asymptomatic gallstones who are unable to access equipped centers in the future.
Patients who have not allergy to enoxaparin.
Do not take anti-coagulant drugs

Exclusion Criteria

Patients with surgical indications with the possibility of absolute rest after surgery
Patients with the possibility of complications such as postoperative bleeding

Study & Design

Study Type: interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
ot occurrence of deep vein thrombosis. Timepoint: The effectiveness of enoxaparin in 24 hours after injection, 72 hours after injection and 14 days after injection. Method of measurement: Presence or absence of deep vein thrombosis examination and follow-up with color Doppler ultrasound and entering its information in a checklist.;Not occurrence of pulmonary embolism. Timepoint: The effectiveness of enoxaparin in 24 hours after injection, 72 hours after injection and 14 days after injection. Method of measurement: Presence or absence of pulmonary embolism by examination and follow-up with CT pulmonary angiography with venous contrast and entering its information in a checklist.

Secondary Outcome Measures